COMMUNIQUÉS West-GlobeNewswire

HeartSciences Adds Key Advisor to its Scientific Advisory Board

26/02/2024 - 15:00

Southlake, TX, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company") , an artificial intelligence (AI)-powered medical technology [...]

PolarityTE Announces First Subject Screened in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers

26/02/2024 - 14:35

SALT LAKE CITY, Feb. 26, 2024 (GLOBE NEWSWIRE) -- PolarityTE today announced the Screening of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational treatment of Wagner grade 1 [...]

Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit

26/02/2024 - 14:30

MALVERN, Pa., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and [...]

Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference

26/02/2024 - 14:30

- Douglas A. Treco, Ph.D., CEO and Chairman, to participate in panel discussion - BOSTON, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease [...]

Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference

26/02/2024 - 14:30

JERUSALEM, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that [...]

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

26/02/2024 - 14:30

Agreement Focuses on Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT and LIXTW ) (“LIXTE” or the [...]

Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications

26/02/2024 - 14:30

Highly selective Small Molecule HDAC6 Inhibitor Effectively Reversed Heart Failure and Improved Diastolic Heart Function Alone or in Combination with SGLT2 Inhibitor in Murine Models of Disease SOUTH SAN FRANCISCO, [...]

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer

26/02/2024 - 14:30

Pamela Stephenson is an accomplished industry executive with over 25 years of global commercial leadership experience and a track record of numerous successful launches WATERTOWN, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE [...]

Carmell Announces Product Development Completed for G.L.E.E. Launch in March 2024

26/02/2024 - 14:30

PITTSBURGH, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell” or the “Company”), today announced that they have completed product [...]

Codexis to Participate in TD Cowen 44th Annual Health Care Conference

26/02/2024 - 14:05

REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the TD Cowen 44 th Annual Health Care Conference, being [...]

Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference

26/02/2024 - 14:05

CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel therapies for rare [...]

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)

26/02/2024 - 14:00

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody ® sonelokimab (SLK) in Hidradenitis Suppurativa (HS) Clarified path for HS Phase 3 [...]

Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference

26/02/2024 - 14:00

Oak Ridge, TN, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the Technology and Heart Failure [...]

Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024

26/02/2024 - 14:00

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet [...]

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

26/02/2024 - 14:00

ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare [...]

PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference

26/02/2024 - 14:00

PRINCETON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting [...]

Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 4

26/02/2024 - 14:00

DUBLIN, Ireland, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a [...]

LifeMD to Report Fourth Quarter 2023 Financial Results on March 11

26/02/2024 - 14:00

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD) , a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 months ended December [...]

Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600

26/02/2024 - 14:00

Data expected to be shared during March corporate update With SAD cohorts complete, MAD cohorts to begin dosing in March SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech [...]